STOCK TITAN

Janux Therapeutics Inc - JANX STOCK NEWS

Welcome to our dedicated news page for Janux Therapeutics (Ticker: JANX), a resource for investors and traders seeking the latest updates and insights on Janux Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Janux Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Janux Therapeutics's position in the market.

Rhea-AI Summary
Janux Therapeutics, Inc. (JANX) reports positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and EGFR-TRACTr JANX008 in solid tumors. JANX007 and JANX008 enrollment ongoing with updates expected in 2H 2024. $344.0 million year-end cash, $320.2 million net proceeds from offering in March. Co-founder promoted to Chief Scientific Officer. Financial results show cash of $344.0 million, decreased R&D expenses, increased net loss. JANX007 and JANX008 advancing in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
earnings
-
Rhea-AI Summary
Janux Therapeutics, Inc. (Nasdaq: JANX) announced the pricing of a public offering, including shares of common stock and pre-funded warrants, to raise approximately $296.5 million. The offering price is $46.50 per share, with additional shares available for purchase by underwriters.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
offering
-
Rhea-AI Summary
Janux Therapeutics, Inc. (JANX) has announced a $175.0 million underwritten public offering of its common stock, with potential additional shares. The company plans to use the proceeds for clinical development and general corporate purposes. BofA Securities, TD Cowen, Cantor Fitzgerald & Co., and William Blair & Company are the joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
offering
Rhea-AI Summary
Janux Therapeutics, Inc. (JANX) announces positive clinical data for JANX007 and JANX008 in metastatic castration-resistant prostate cancer and late-stage solid tumors. The data show promising efficacy and safety profiles, with encouraging results in heavily pretreated subjects. JANX007 achieved significant PSA declines, while JANX008 displayed differentiated safety and efficacy in various solid tumor types. Janux aims to address unmet medical needs for cancer patients with its TRACTr and TRACIr platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
229.47%
Tags
none
-
Rhea-AI Summary
Janux Therapeutics, Inc. (JANX) to host a virtual event discussing updated clinical data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008. The event will take place on Monday, February 26th, 2024, at 4:30PM ET. JANX007 targets prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer, while JANX008 targets epidermal growth factor receptor (EGFR) for various cancers. Janux is developing a broad pipeline of novel immunotherapies with TRACTr and TRACIr platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
conferences clinical trial
-
Rhea-AI Summary
Janux Therapeutics, Inc. (JANX) announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer. Dr. DiRaimondo has played a pivotal role in developing the company's Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms. Janux is advancing its first clinical candidate, JANX007, targeting PSMA, and its second candidate, JANX008, targeting EGFR, in Phase 1 clinical trials for the treatment of various solid cancers. The company is also developing a TRACTr targeting TROP2 and a TRACIr candidate, JANX009, for the treatment of solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
none
Rhea-AI Summary
Janux Therapeutics, Inc. (JANX) Reports Enrollment Ongoing for PSMA-TRACTr (JANX007) in Prostate Cancer and EGFR-TRACTr (JANX008) in Solid Tumors, Expects Update on Clinical Programs in 2024 with $349.7 Million in Cash and Investments at End of Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
earnings
-
Rhea-AI Summary
Janux Therapeutics, Inc. (JANX) Announces Pricing of Underwritten Offering, Expected to Raise $60 Million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
clinical trial
Janux Therapeutics Inc

Nasdaq:JANX

JANX Rankings

JANX Stock Data

1.95B
18.61M
13.78%
82.35%
6.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About JANX

janux therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary tumor activated t cell engager (tractr) platform technology to better treat patients suffering from cancer. janux’s initial focus is on developing a novel class of t cell engagers (tces), and its lead product candidates are designed to target clinically validated drug targets. while tce therapeutics have displayed potent anti-tumor activity in hematological cancers, developing tces to treat solid tumors have faced challenges due to the limitations of prior tce technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. janux is using its tractr platform technology to engineer product candidates designed to overcome these limitations. janux is developing a broad pipeline with lead programs targeting prostate-specific membr